Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.1651
+0.0051 (3.19%)
At close: Sep 16, 2026, 4:00 PM EDT
0.1594
-0.0057 (-3.45%)
Pre-market: Sep 17, 2026, 8:50 AM EDT
Matinas BioPharma Holdings Employees
Matinas BioPharma Holdings had 2 employees as of December 31, 2025. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$3,654,500
Market Cap
2.43M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2 | -1 | -33.33% |
| Dec 31, 2024 | 3 | -29 | -90.63% |
| Dec 31, 2023 | 32 | -2 | -5.88% |
| Dec 31, 2022 | 34 | 3 | 9.68% |
| Dec 31, 2021 | 31 | 11 | 55.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 33 |
| Calidi Biotherapeutics | 29 |
| Tessera Defense and Homeland Security | 20 |
| GeoVax Labs | 19 |
| Genprex | 13 |
| Artelo Biosciences | 7 |
| CDT Equity | 4 |
| SciSparc | 3 |
MTNB News
- 3 days ago - GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output - GlobeNewsWire
- 12 days ago - Matinas BioPharma receives noncompliance notifcation from NYSE - TheFly
- 12 days ago - Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - GlobeNewsWire
- 5 weeks ago - Matinas BioPharma Holdings Quarterly report: Q2 2026 - Filings
- 2 months ago - Matinas BioPharma teams with GH Power to create publicly-traded company - TheFly
- 2 months ago - Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals - GlobeNewsWire
- 2 months ago - Matinas BioPharma receives noncompliance notification from NYSE - TheFly
- 2 months ago - Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance - GlobeNewsWire